You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

368 Results
Drug
Other Name(s): Calquence®
Dec 2025
Drug
Other Name(s): Verzenio®
Dec 2025
Drug
Other Name(s): Arimidex®
Dec 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), based on criteria
Dec 2025
Drug
Other Name(s): Tecentriq™
Jul 2025
Guidelines and Advice
Status: In-Review
ID: 17-1
Version: 2
Mar 2015
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025
Guidelines and Advice

Pages